Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
473 matching companiesShowing 73–96 / 473
The 2026-10-12 announcement reports the first participant enrolled in Phase 3 DAYBreak CLL-306. NX-5948 is an oral, brain-penetrant BTK degrader. The company also reported collaboration progress with Roche, Gilead, Pfizer, and Sanofi.
CLIPS™ supports monocyclic, bicyclic, and tricyclic constrained peptides, screening, and optimization. Recorded at the integrated-group level; oral suitability requires program-level validation.
The company describes constrained peptide chemistry involving disulfides, lactam bridges, stapling, and other cyclization approaches. This review did not confirm a proprietary oral cyclic peptide candidate.
MAUD 1.0 combines generative AI, physics-based modeling, and quantum simulations to design cyclic peptides. The company explicitly optimizes oral bioavailability and cell permeability and works with pharmaceutical partners on discovery.
An October 2026 research collaboration and exclusive option agreement with Generian advances an oral macrocyclic peptide FcRn antagonist. This research-stage program is separate from Processa’s Phase 2 small-molecule BTK inhibitor VT-7208.
A company emerging from the UPMC/University of Pittsburgh ecosystem, Generian entered an October 2026 research collaboration and exclusive option arrangement with Processa for an oral macrocyclic peptide FcRn antagonist.
A cyclic peptide discovery company using trillion-scale peptide libraries, screening, and chemical optimization for internal programs and partnerships. Its website identifies oral peptide therapeutics as one potential application.
AC699 (also called AC0699 on the website) is an oral ERα chimeric degrader. Phase 1 human results and FDA Fast Track were reported in 2024.
Offers integrated structural biology, AI design, cyclic peptide synthesis, DMPK, and process-development capabilities. A September 2026 company article discusses oral cyclic peptide bioavailability, impurity control, and scale-up.
Holds exclusive development, manufacturing, and commercialization rights for linaclotide in Japan. It is included as a regional partner for an approved, locally acting oral disulfide-constrained peptide.
Ironwood’s Q2 2026 filing confirms that Grand Life Sciences assumed AstraZeneca’s linaclotide development, manufacturing, and commercialization rights in China, including Hong Kong and Macau, in May 2026.
Aurinia’s Q3 2026 filing identifies Otsuka as the development and commercialization partner for oral voclosporin in Japan, the EU, the UK, and other specified territories, supported by a commercial supply arrangement.
The company describes AUTAC as comprising an autophagy-recruiting group, target ligand, and linker. Its website does not list named candidates or clinical stages.
The original 2022 study demonstrated the p62-mediated AUTOTAC platform. A 2026 investigator conference abstract still describes IND-enabling preclinical work in neurodegenerative disease.
PAQ develops KRAS degraders. The registered Phase 1 PT0253 study is in advanced solid tumors with KRAS G12D mutations. Historical autophagy positioning was not substituted for current technical disclosures.
Provides cyclic and other complex peptide synthesis, noncanonical amino-acid modifications, peptide libraries, and in vitro oral-bioavailability screening. It is included as a discovery and development service provider.
A publicly traded mRNA drug company with a disclosed platform spanning mRNA design, LNP delivery, and drug substance and drug product manufacturing.
The 2026-08-11 announcement reports ongoing Phase 2 MOMENTUM and Phase 1b cemsidomide plus elranatamab studies. Phase 1 results were announced in June. A 2026 quarterly report describes other platform collaborations; MSD's DAC agreement ended in November 2025.
The website reports Novartis licensing of the VAV1 molecular glue MRT-6160 and Phase 2 studies. The NEK7 molecular glue MRT-8102 completed Phase 1 GFORCE-1; MRT-2359 is in clinical combination development.
The website defines PLX-61639 as an oral, selective, monovalent SMARCA2 direct degrader and lists its clinical study. PLX-66140 is a CDK2 CRBN molecular glue.
The 2026-02-03 announcement reports first dosing in the Phase 1/2 NEO-811 renal cancer trial. The company pipeline identifies ARNT/HIF-1β as its target and lists pharmaceutical collaborations.
The website describes ORICISION as discovering both protein degraders and conformational correctors, emphasizing patient-derived models and clearance of disease-associated proteins.
AMX-883, first dosed in October 2026, is a DCAF16-mediated BRD9 Targeted Glue. The company previously disclosed collaborations with BMS and Merck KGaA.
An original 2026 ASCO abstract by company researchers describes CT-01 as a GSPT1/NEK7 dual-target molecular glue. Phase 1 began in May 2025, studying monotherapy and combination with everolimus in hepatocellular carcinoma.
Coverage expands from sourced records; this database does not claim all biopharma companies.
